CTOs on the Move


 
Healix Ltd is a Sugar Land, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.healix.com
  • 14140 Southwest Fwy Ste 400
    Sugar Land, TX USA 77478
  • Phone: 281.295.4000

Executives

Name Title Contact Details

Similar Companies

Anne Arundel Dermatology

With modern, attractive clinical offices in Annapolis, Glen Burnie, Hagerstown, Prince Frederick, Leonardtown, Kent Island, and Easton, 19 board certified physicians, 7 physician assistants, 2 certified nurse practitioners, a full service cosmetic lase...

JandS Studies

J&S Studies, Inc. is a Bryan, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.

Clinuvel

Clinuvel is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.